预约演示
更新于：2025-11-28
Gallium GA-68 Gozetotide
镓[68Ga]戈泽肽
更新于：2025-11-28
概要
基本信息
药物类型 多肽偶联核素、诊断用放射药物 |
别名 (68)Ga Labeled Glu-NH-CO-NH-Lys(ahx)-hbed-CC、(68)Ga-labeled Glu-urea-Lys(Ahx)-HBED-CC、(68Ga)Glu-urea-Lys(Ahx)-HBED-CC + [33] |
靶点 |
作用方式 抑制剂 |
作用机制 PSMA抑制剂(前列腺癌特异性膜抗原抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2020-12-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C44H55GaN6O17 |
InChIKeyAEBYHKKMCWUMKX-LNTZDJBBSA-G |
CAS号1906894-20-9 |
使用我们的ADC技术数据为新药研发加速。
登录
或
关联
131
项与 镓[68Ga]戈泽肽 相关的临床试验NCT06881823
NeoPSMA: A Phase I/II, Open-label, Multi-center Study of Neoadjuvant Treatment With [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Adults With Prostate-specific Membrane Antigen (PSMA) Positive High-risk Localized Prostate Cancer (HRLPC) Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection
NCT07150715
Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide Combined With Metastasis-Directed Stereotactic Body Radiotherapy for Oligorecurrent Prostate Adenocarcinoma (ANDROMEDA)
NCT07052214
A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).
100 项与 镓[68Ga]戈泽肽 相关的临床结果
登录后查看更多信息
100 项与 镓[68Ga]戈泽肽 相关的转化医学
登录后查看更多信息
100 项与 镓[68Ga]戈泽肽 相关的专利（医药）
登录后查看更多信息
249
项与 镓[68Ga]戈泽肽 相关的文献（医药）2025-12-01Current Urology Reports
The Role of PSMA PET Imaging in Prostate Cancer: Current Applications and Future Directions
Review
作者: Golombos, David M ; Moran, Melissa ; Islam, Raeesa ; Desai, Shrijal
Abstract:
Purpose of Review:
Prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging has revolutionized prostate cancer detection and management. This review aims to evaluate the latest advancements in PSMA PET imaging, assess its clinical applications in various disease stages, and compare it to conventional imaging techniques. We sought to determine how PSMA PET impacts clinical decision-making, treatment strategies, and patient outcomes, with a focus on its expanding role in precision oncology.
Recent Findings:
Recent studies have demonstrated that PSMA PET exhibits superior sensitivity and specificity in detecting prostate cancer metastases, particularly in cases of biochemical recurrence and early-stage disease. The advent of radiolabeled PSMA ligands, such as 68Ga-PSMA-11 and 18 F-DCFPyL, has led to improved diagnostic accuracy. Furthermore, PSMA-targeted radioligand therapies (e.g., 177Lu-PSMA-617) show promising results in metastatic castration-resistant prostate cancer (mCRPC), offering a novel therapeutic avenue. Studies have also highlighted the role of PSMA PET in refining treatment plans, including guiding surgery and radiotherapy.
Summary:
PSMA PET imaging represents a paradigm shift in prostate cancer diagnostics, staging, and treatment monitoring. It has led to earlier and more accurate detection of metastases, significantly altering management strategies. The growing body of evidence supports its integration into standard-of-care protocols, with ongoing research focusing on optimizing its therapeutic applications. Future studies should explore cost-effectiveness, accessibility, and potential synergies with emerging systemic therapies to further enhance patient outcomes.
2025-11-01Nature Protocols
Byproducts in the synthesis of [68Ga]Ga-PSMA-11
Letter
作者: Han, Jianlin ; Makarem, Ata ; Klika, Karel D
2025-09-11CLINICAL NUCLEAR MEDICINE
Inter-tumor Heterogeneity of 68Ga-PSMA-11 Uptake in Metastatic Undifferentiated Sarcoma.
Article
作者: Bai, Yushu ; Xiao, Zhengguang ; Wang, Yang ; Dong, Aisheng ; Zuo, Changjing
Immunohistochemical studies show PSMA may be a potential target for molecular imaging and treatment in bone and soft tissue sarcomas. We describe 68Ga-PSMA-11 PET/CT findings in a case with metastatic undifferentiated sarcoma. The sarcoma lesions showed a high variability of 68Ga-PSMA-11 uptake measured by SUVmax, ranging from 3.2 to 21.5. This case indicates that undifferentiated sarcoma can show increased PSMA uptake, 68Ga-PSMA-11 PET may noninvasively evaluate the inter-tumor heterogeneity of PSMA expression, and PSMA-targeted radioligand therapy may be a promising therapeutic option for this aggressive sarcoma.
100 项与 镓[68Ga]戈泽肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| PSMA阳性前列腺癌 | 德国 | 2025-01-15 | |
| PSMA阳性去势抵抗性前列腺癌 | 欧盟 | 2022-12-09 | |
| PSMA阳性去势抵抗性前列腺癌 | 冰岛 | 2022-12-09 | |
| PSMA阳性去势抵抗性前列腺癌 | 列支敦士登 | 2022-12-09 | |
| PSMA阳性去势抵抗性前列腺癌 | 挪威 | 2022-12-09 | |
| 转移性前列腺癌 | 澳大利亚 | 2021-11-10 | |
| 前列腺癌 | 美国 | 2020-12-01 | |
| 前列腺癌 | 美国 | 2020-12-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 非转移性前列腺癌 | 临床3期 | 中国 | 2023-07-19 | |
| 非转移性前列腺癌 | 临床3期 | 中国 | 2023-07-19 | |
| 转移性去势抵抗性前列腺癌 | 临床3期 | 美国 | 2022-05-09 | |
| 涎腺多形性腺瘤 | 临床3期 | 美国 | 2017-05-20 | |
| 复发性前列腺癌 | 临床3期 | 美国 | 2016-09-15 | |
| 前列腺腺癌 | 临床3期 | 美国 | 2016-04-18 | |
| 腺样囊性癌 | 临床2期 | 美国 | 2024-08-12 | |
| 胶质瘤 | 临床2期 | 美国 | 2024-07-26 | |
| 脑恶性胶质瘤 | 临床2期 | 美国 | 2024-07-26 | |
| 复发性胶质瘤 | 临床2期 | 美国 | 2024-07-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 163 | Computed Tomography+Gallium Ga 68 Gozetotide | 構齋遞糧窪製鬱構餘網 = 選窪壓壓繭齋鏇鬱醖壓 憲糧衊窪遞遞廠鹽壓鏇 (壓願製糧鹽鹽艱餘蓋襯, 廠鹽衊糧糧夢觸鬱網鑰 ~ 鹽鑰獵築繭獵窪糧夢選) 更多 | - | 2025-07-09 | ||
临床2/3期 | 6 | 遞範憲鹹鏇鹽糧積鏇範 = 壓餘鬱積窪鏇夢餘夢膚 醖製膚夢襯製衊網餘餘 (窪餘夢齋夢鹽醖鏇觸膚, 糧襯齋鹹鏇範鏇衊鏇鑰 ~ 願壓襯齋糧觸簾顧構鹹) 更多 | - | 2025-04-17 | |||
N/A | 462 | (PSA <0.5 ng/mL + Imaging Prior to Suspected Recurrence Therapy) | 簾艱膚積製鹽願衊範餘(艱鬱顧鏇夢範範簾鏇齋) = 淵蓋襯艱鏇鏇窪鏇觸夢 鹹繭獵鏇網鏇獵顧糧繭 (鏇範網觸夢衊窪繭蓋繭, 27 ~ 44) | 积极 | 2025-03-20 | ||
(PSA ≥0.5 and <1 ng/mL + Imaging Prior to Suspected Recurrence Therapy) | 簾艱膚積製鹽願衊範餘(艱鬱顧鏇夢範範簾鏇齋) = 鹹製鏇齋鬱齋蓋鹽鬱蓋 鹹繭獵鏇網鏇獵顧糧繭 (鏇範網觸夢衊窪繭蓋繭, 45 ~ 67) | ||||||
N/A | 123 | (Imaging Prior to Initial Definitive Therapy) | 醖製糧製觸淵獵鏇衊膚(膚鹽顧觸築繭範獵壓糧) = 繭選鹽蓋網鹹製餘觸鏇 範顧廠夢鹽鑰鑰醖選簾 (襯襯範艱醖積壓膚艱淵, 29 ~ 65) 更多 | 积极 | 2025-03-20 | ||
临床2期 | 7 | 範願餘廠廠網膚鏇鬱襯 = 願願窪壓鏇觸鹽網遞鏇 膚鹽衊淵願鏇築範艱糧 (窪鏇積顧憲顧糧遞蓋範, 築鹽獵願構蓋簾築遞艱 ~ 範鬱顧淵鑰觸夢遞網觸) 更多 | - | 2025-02-28 | |||
临床2期 | 15 | Positron Emission Tomography (PET)+68Ga-PSMA-11 | 襯構鬱憲襯廠窪壓衊遞 = 壓簾淵構獵選遞艱醖繭 網獵築獵糧壓餘憲網構 (觸壓壓鹹積鏇齋積選壓, 製鬱構鬱憲齋壓醖鬱齋 ~ 鹽鏇遞夢窪壓觸製衊衊) 更多 | - | 2024-10-16 | ||
临床2/3期 | 30 | 廠蓋餘網鏇衊窪獵艱醖 = 壓夢獵積鑰餘積蓋艱廠 獵簾簾壓蓋齋鏇壓鹽餘 (繭廠顧窪築鹽遞衊醖壓, 網醖糧鑰顧鹹遞憲選壓 ~ 選鏇醖衊範築壓繭鹽簾) 更多 | - | 2024-06-28 | |||
临床1期 | 10 | 範夢膚積簾鏇鬱壓憲鏇 = 鏇鑰觸築構壓齋醖範遞 網觸製艱鑰鹽願壓鏇顧 (糧齋築製範壓夢窪醖築, 夢齋糧夢餘齋鬱艱網醖 ~ 鬱製構衊淵齋製範選鬱) 更多 | - | 2024-04-26 | |||
临床2/3期 | 22 | 範蓋廠鹹願鬱夢繭膚艱 = 壓衊壓網夢簾築構鏇鹽 願襯廠築構簾醖獵餘窪 (願壓壓鏇獵襯壓製鏇積, 願襯積鑰齋簾醖衊築簾 ~ 憲衊廠壓範鏇鹹膚齋獵) 更多 | - | 2024-02-15 | |||
临床2期 | 4 | (68Ga-RM2 PET MRI) | 觸製顧築願壓醖衊選願 = 艱夢選齋簾衊蓋獵積製 壓顧醖鏇齋鑰鹽選鹽範 (願鬱壓鏇廠築齋繭選壓, 繭糧窪窪簾齋獵繭鹽鹽 ~ 蓋糧鹹淵觸獵鹹憲繭廠) 更多 | - | 2024-02-01 | ||
(68Ga-PSMA-11 PET MRI) | 觸製顧築願壓醖衊選願 = 構築獵餘淵遞醖蓋廠鹹 壓顧醖鏇齋鑰鹽選鹽範 (願鬱壓鏇廠築齋繭選壓, 窪構齋顧廠衊選壓選構 ~ 簾選繭獵築糧壓遞鹽憲) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用